Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 clinical trial evaluating the efficacy and safety of ART-648 in patients with bullous pemphigoid

Next Previous
Trial Profile

Phase 2 clinical trial evaluating the efficacy and safety of ART-648 in patients with bullous pemphigoid

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAK 648 (Primary)
  • Indications Bullous pemphigoid
  • Focus Therapeutic Use
  • Sponsors ARTham Therapeutics

Most Recent Events

  • 12 Apr 2023 Status changed from recruiting to discontinued, according to a Kaken Pharmaceutical media release.
  • 12 Apr 2023 According to a Kaken Pharmaceutical media release, the company has decided to discontinue development of ART-648 for bullous pemphigoid based on results from this study. None of all the enrolled patients, who had been administered ART-648 or placebo to date, showed cessation of new lesion formation, the trial's primary endpoint. Further, the enrollment of participants in the trial was not progressing as planned, therefore the company decided to discontinue this trial half-way.
  • 30 Nov 2021 According to an ARTham Therapeutics media release, the company has been acquired by Kaken Pharmaceutical Co. LTD. and the company will become a wholly-owned subsidiary of Kaken on a voting basis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top